Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2012

STA Licenses Cancer Cachexia Drug

  • Swiss pharma firm Helsinn granted Specialised Therapeutics Australia (STA) exclusive commercialization rights in Australia and New Zealand to its Phase III-stage ghrelin receptor agonist, anamorelin, for the treatment of non-small cell lung cancer cachexia-anorexia.

    STA has already successfully commercialized Helsinn’s 5-HT3 antagonist Aloxi® (palonosetron), and holds a license to the firm’s Phase III-stage fixed dose netupitant-palonosetron combination therapy for preventing chemotherapy-induced nausea and vomiting. Under terms of the latest anamorelin deal, STA will be responsible for regulatory/clinical development and commercial activities within Australia and New Zealand.

    There are currently no approved therapies for treating muscle wasting and more generally cachexia-anorexia in cancer patients, the firms note. Helsinn’s anamorelin is currently undergoing two Phase III trials, Romana 1 and Romana 2, as at treatment for cachexia-anorexia in patients with NSCLC. The two studies will enroll about 477 patients in over 15 countries, and patients who complete Romana 1 or Romana 2 and opt to continue on anamorelin therapy will be enrolled into an extension safety study, Romana 3. Pending positive trial results, an NDA filing with FDA is anticipated in mid-2014, followed immediately by regulatory filing in Australia. 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »